BREVICON 28-DAY
LOE ApproachingNDAORAL-28TABLET
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BREVICON 28-DAY is an oral contraceptive tablet approved in 1976 containing a combination of norethindrone and ethinyl estradiol. The product prevents pregnancy through hormonal suppression of ovulation and alteration of cervical mucus. It is a foundational small-molecule oral contraceptive with a 28-day dosing cycle.
LOE Approaching
Mature legacy product nearing loss of exclusivity; brand team likely focused on retention and lifecycle management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BREVICON 28-DAY is a legacy asset with zero linked job openings, reflecting minimal active career development. Roles remaining are primarily defensive and focused on customer retention, pricing, and managed-care negotiations rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on BREVICON 28-DAY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.